Wedescribe a 27-year-old womanwith disseminated intravascular coagulation and shock due to amniotic fluid embolismafter Caesareansection whoresponded well to continuous hemodiafiltration (CHDF) therapy. The effectiveness of CHDFin treating amniotic fluid embolism is also discussed. (Internal Medicine 40: 945-947, 2001) 
Introduction
Amniotic fluid embolism (AFE) is a fatal disease. Since the precise pathophysiological mechanismof AFEhas not been elucidated, no specific treatment has been established. In this article, we report a patient with AFEand propose a novel modality for the treatment of AFE.
Case Report
A previously healthy 27-year-old para 0, gravida 0 woman was admitted to Hiratsuka City Hospital in July 1999 for vaginal bleeding due to imminent premature labor at 28 weeks gestation. Dilatation of the cervix and cervicitis werenot observed. The cause of the imminent premature labor could not be elucidated. Both mother and fetus were well conditioned by the administration of ritodrine hydrochloride. At 38 weeks of gestation, Caesarean section was performed under lumbar anesthesia with dibucaine hydrochloride because of pelvic presentation. Seventeen minutes after the start of the operation, a 2,676 g female infant was delivered. The neonatal Apgar score was 7 and 8 at one minute and five minutes, respectively. Noplacenta abnormalities were observed.
Excessive vaginal bleeding was observed despite a wellcontracted uterus. Three and a half hours after the operation, the woundwas resutured because of persistent non-clotting bleeding. An ultrasound examination showed no signs of bleeding in the abdominal cavity. Four hours after the operation, the patient went into shock. The hemoglobin concentration in the patient' s blood had decreased from 10.7 g/dl to 3.4 g/dl. Six and a half hours after the operation, her blood pressure was 46/ 22 mmHg and she was tachycardic (140 beats per minute). Septic shock was excluded as a diagnosis because of the sudden onset of cardiovascular collapse immediately after the operation. She was treated with packed red cells, isotonic solution, and intravenous infusion of dopamine hydrochloride. such as abruption of the placenta, placenta previa, and atonic hemorrhage, were excluded. Fresh frozen plasma, platelet rich plasma, gabexate mesilate, and humananti-thrombin III were administered to treat the DIC. About 9 hours after the Caesarean section, continuous hemodiafiltration (CHDF) using a highly permeable polyacrylonitrile hollow fiber membrane (APF-06S, Asahi Medical Co., Ltd., Japan) was performed by exchanging the extracellular fluid for artificial extracellular fluid solution at a rate of 200 ml per hour. The informed consent of the patient and her husband was obtained prior to the start of CHDFtreatment. Fourteen hours after the CHDF was started, the patient's general condition improved, and the dose of dopamine hydrochloride was reduced from 15 |ig/kg/min to 5 |Lig/kg/min. Twenty-two hours after the initiation of CHDF,the procedure was discontinued because the laboratory data had improved (PT 1 1.0 seconds, APTT 47.7 seconds, fibrinogen 460 mg/dl, FDP 20-40 |ig/ml, AT-III 103.0% and platelets 133,OOO/|il). The patient subsequently improved from day to day. Twenty days after the operation, the mother and infant were discharged without any further complications.
Sialyl Tn structure (NeuAcoc 2-6 GalNAca 1-0-Ser/Thr), which is recognized by monoclonal antibody TKH-2 (2), and zinc coproporphyrin-I (3) were both measured in the maternal peripheral blood, where their source is meconiumin amniotic fluid. Although their concentrations were within the normal range (12.5 U/ml and 0.4 pmol/ml, respectively), these values did not rule out AFE(4).
Discussion
AFEis a frightening and devastating disease, and the rigid diagnostic criteria for AFEis one of the reasons for its high mortality rate. Therefore, physicians must take therapeutic ac- less than or equal to 60 mmHg;2) sustained tachycardia (greater than or equal to 140 beats per minute) for 4 hours; 3) absence of other illnesses that would explain the signs and symptoms (eg, sepsis, pulmonary embolism, myocardial infarction). The definition should also distinguish between type 1 AFEwith DIC (laboratory or clinical) and type 2 AFE without DIC. In this definition, DIC must include thrombocytopenia and elevated fibrin degradation products occuring within 4 hours of the initial cardiovascular collapse. Adult respiratory distress syndrome was not included in the definition. If Benson's definition becomes widely used, the prevalence of recognized AFEcases may increase significantly. Since the definition should permit the inclusion of a larger number of patients whosurvive, one wouldalso expect a corresponding drop in the mortality rate for this condition (1). Benson' s definition also permits a reduction in the AFEmortality rate because of early diagnosis and early treatment.
In the present case, the patient met the criteria for type 1 AFEand responded well to CHDFtherapy. CHDFenables a continuous exchange of extracellular fluid, which contains meconium in the amniotic fluid, with an artificial extracellular solution and can removemanysubstances with a molecular weight (MW) of up to 30 kD to 40 kD (5). Removal ofcytokines, such as interleukin-6 (MW2 1 kD) and interleukin-8 (MW 8 kD), using CHDFis a reasonable method for treating hypercytokinemia, which can cause multiple organ failure (MOF) (5) .
Consideration must be given to which is better for the treatment ofAFE, CHDFor continuous hemofiltration (CHF). CHF is more effective at eliminating high molecular weight substances than CHDF;however, CHDFis more effective than CHFfor the treatment of metabolic acidosis. Therefore, we selected CHDFfor the treatment of AFE.
Treatment for DICconsists of ®treatment for the causative disease and ® general treatment for the symptomsof DIC. Treatment for shock consists of (D treatment for the causative disease and 0 general treatment for the symptoms of shock. The use of CHDFto treat AFE followed by DIC and shock enables all of the above treatments to be provided (®+ ®+(D+®)because CHDFcan eliminate amniotic fluid from the maternal blood stream and can correct the hyper-cytokinemia and metabolic acidosis produced by amniotic fluid leakage.
CHDFmust be continued for 1 to 3 weeks in patients with MOFdue to pancreatitis, because the damaged pancreas produces many humoral factors for a long period. However, only short-term CHDFmay be needed in AFE, because the total amount and duration of amniotic fluid leakage into the maternal blood stream are limited. Since AFEis a rare condition, no single institution has sufficient experience to assess the effectiveness of CHDF therapy. However, we think that CHDFmay be a novel modality for the treatment of AFE.
